Paragon 28 (FNA) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Market Overview and Positioning

• The global foot and ankle market is valued at $5.2 billion in 2024, with the U.S. comprising 50-55% and projected to reach $6.9 billion by 2029 at a 7.2% CAGR.

• The lower extremity market is complex, under-researched, and has high complication rates, offering significant opportunities for innovation.

• Five subsegments within the market allow for a balanced and diversified portfolio across trauma and elective procedures.

• Paragon 28 holds about 7% U.S. and 1% international market share, with sales growth outpacing the segment by 2–3x since IPO.

• The company aims to become the first pure-play billion-dollar foot and ankle company, focusing on technology and expanding its surgeon user base.

Product Innovation and Technology

• Over 80 product solutions have been developed since 2010, with 20+ active projects and 13 new products launched in 2024, including Smart Bun-Yo-Matic, Phantom Fibula Nail, and APEX 3D systems.

• 2024 marked a strong year for product launches, including advancements in 3D modeling for patient-specific solutions.

• Innovations address diagnostics and intraoperative precision, such as the Bun-Yo-Matic clamp and dynamic syndesmotic fixation tools.

• Emphasis on unbiased research, medical education, and mobile labs, with over 3,500 surgeons trained in person in the last 12 months.

• Focus on patient-specific instruments and reducing surgical complications through technology and data-driven insights.

Financial Performance and Operational Strategy

• Reported 18.3% year-over-year growth, with 2024 revenue guidance at $255.9M–$256.9M and Q4 results above expectations.

• Achieved adjusted EBITDA profitability in 3Q24 for the first time since IPO, driven by restructuring and a 7% reduction in force, saving $8M annually.

• Gross margin target set at 75%+, with improvements as higher-cost inventory is sold off and operating expenses as a percentage of revenue improving by 969 and 500 basis points YoY and sequentially in 3Q24.

• Free cash flow improved by 69.5% YoY and 54.7% sequentially in 3Q24, supported by better inventory and accounts receivable cycles.

• Commitment to being EBITDA positive in 2025 and cash flow positive in 2026, supported by inventory and working capital management.